Lotal (Nitroxoline) is commonly used across conditions presenting with acute episodes of urogenital infection. Its primary therapeutic application is the management of urogenital infections. The drug may be used as part of symptomatic management for both acute and chronic urinary tract infections. It is applied in addressing symptom clusters that may become intense or disruptive, such as painful urination (dysuria), urgency, and frequency, characteristic of conditions like acute cystitis. It is considered relevant in situations involving recurrent infection patterns and against multi-drug resistant (MDR) uropathogens and susceptible fungi.

The medication is applied to help reduce the incidence of subsequent symptomatic episodes, supporting the patient during difficult episodes by easing distress. Lotal provides support that helps ease the overall symptom burden and assists with maintaining functional stability during symptomatic periods.

---

Key Therapeutic Indications

The medication is relevant for acute cystitis, management of recurrent urinary tract infection patterns, and use against certain multi-drug resistant uropathogens and susceptible fungi.

---

Quick Fact: Relief for Acute Symptoms
Lotal is often used during phases when symptoms become more noticeable, particularly to help manage lower urinary discomfort and help manage symptom recurrence.

Who Can and Cannot Use Lotal?

The official regulatory documents define the eligible population for Lotal (Nitroxoline) based on specific physical conditions and age thresholds.

Populations Excluded from Use (Contraindications)

Use of Lotal is contraindicated in several specific populations, meaning the medicine must not be used:

• Patients with known Hypersensitivity to the active substance, Nitroxoline, or any related quinolines.
• Patients with Severe Hepatic Impairment.
• Patients with Severe Renal Impairment. Regulatory labeling defines this severity as a creatinine clearance of less than 0.33 ml/sec.

Age and Condition-Based Eligibility

Lotal is approved for use in Adults and Children aged mathbf4 years and older. Use of the medicine is not established or is prohibited for children younger than mathbf4 years of age. For physiological states such as Pregnancy and Lactation, the eligibility status is not explicitly documented in the official contraindication or restricted-use sections.

The overall eligibility profile is structured primarily around these absolute exclusions, ensuring the medicine is not used in individuals with organ function limits or chemical class allergies.

The official regulatory profile for Lotal (Nitroxoline) identifies specific pharmacokinetic and pharmacodynamic interactions, focusing on effects on co-administered medicines and on Lotal's own systemic exposure. All interaction statements are derived from official government-based regulatory documents.

---

Documented Exposure-Modifying Interactions

Co-administration with certain medicinal products may alter their effectiveness, which is categorized as an exposure-modifying interaction.

Interacting Substance Category	Formal Interaction Outcome
Oral Anticoagulants (Coumarin derivatives, e.g., Warfarin)	May result in an increase in the therapeutic efficacy of the anticoagulant.

---

Documented Interactions with Supplements and Products

Official documents note a significant pharmacokinetic interaction with products containing multivalent metal ions, which reduces Lotal's systemic uptake.

Interacting Substance Category	Formal Interaction Outcome
Divalent or Trivalent Cations (e.g., Iron, Zinc, Magnesium, Calcium, and products like Antacids)	Co-administration causes decreased absorption/bioavailability of Lotal (Nitroxoline).

---

Regulatory Classifications and Restrictions

No medicinal products are formally classified as a contraindicated combination in the official regulatory documents. Additionally, a universally mandated, explicitly written time-separation requirement for administration is not specified in the reviewed regulatory interaction sections, despite the documented absorption risk.

Lotal's pharmacological activity is exclusively bacteriostatic, relying on a cascade that modulates essential biological functions within susceptible microorganisms. Its mechanism operates across three primary domains.

Metal Ion Sequestration and Metabolic Shutdown

Lotal acts as a metallophore, engaging in chelation by binding to and sequestering essential metal cofactors (like ferrous ( Fe^2+) and zinc ( Zn^2+)) required for microbial enzyme function. This molecular event leads to the functional inactivation of key metal-dependent enzymes, notably Ribonucleotide Reductase ( RNR). This process initiates a sequence that leads to the physiological effect of arrested microbial proliferation.

Replication Blockade and Growth Control

The functional failure of RNR directly results in a cascade that blocks the synthesis of essential DNA and RNA building blocks, thereby limiting bacterial replication and cell division. This mechanistic interference with the microbial nucleic acid synthesis pathway results in the bacteriostatic effect that restricts microbial growth.

Biofilm Disruption and Virulence Pathway Modulation

Beyond growth inhibition, the mechanism actively disrupts the community structures that microbes use for colonization. Lotal limits the pathogen's ability to adhere to host surfaces and compromises the stability of established biofilms and the signals used for Quorum Sensing. This activity restricts the pathogen's colonization potential by compromising the structural components of the microbial population.

How Lotal is Used

Lotal (Nitroxoline) is administered exclusively through the oral route. The medication is typically available as an oral solid preparation, such as a tablet or capsule, for swallowing. For situations requiring precise weight-based administration, particularly in pediatric patients, an oral suspension form is also utilized. The principles of use are defined by the required dosing, administration schedule, and overall duration, differentiating between treatment and prevention contexts.

---

Standard Dosing and Frequency

For acute treatment in adults, the standard regimen involves a total daily dose of 750 mg, administered in 250 mg portions. This total amount is given in divided daily doses, typically scheduled as three times daily (t.i.d.) or approximately every 8 hours. Adherence to this schedule is necessary to maintain consistent levels of the active substance. When used for prophylaxis against infection recurrence, the total daily dose is lower, ranging from 300 mg to 500 mg.

---

Duration and Special Populations

The protocol for Lotal use is segmented by duration. Treatment for acute conditions is defined as a short-term course, generally lasting between 3 to 10 days. Conversely, the prophylactic use against recurrence requires a long-term course, often extending for 2 to 3 months. For pediatric patients, administration rules are weight-based, requiring a daily dose between 10 mg/kg/day and 20 mg/kg/day, which is also administered in divided daily portions.

Research Evidence Overview for Lotal

This section outlines the landscape of official research and studies that have been conducted on Lotal (Nitroxoline), detailing the types of evidence available, the patient populations examined, and the specific outcomes that researchers were monitoring. It strictly relies on findings reported in authoritative sources and does not provide clinical guidance or treatment advice.

---

Evidence for Use in Acute Bladder Infections (Uncomplicated UTI)

The research for Lotal's use in acute bladder infections is often presented through systematic reviews and meta-analyses that synthesized findings from controlled clinical studies. These studies primarily examined outcomes related to physical discomfort and biological markers in adult women experiencing typical acute episodes.

Research monitored two key outcomes: Microbiological Eradication, which assessed whether the infecting bacteria were reduced or cleared from the urine, and Clinical Cure Outcomes, which described how patients reported the evolution of symptoms such as painful urination and urgency. Findings describe patterns observed in the studies where the measured outcomes for Lotal were similar to those reported for older comparative agents.

---

Evidence for Preventing Recurrent Infections

Lotal was also evaluated in a research context exploring its long-term use for the prophylaxis, or prevention, of recurrent urinary tract infections (rUTI). This evidence is primarily drawn from observational settings and older clinical trials. Studies monitored the frequency of subsequent symptomatic episodes during the period of continuous administration, and findings describe patterns where a lower incidence of infection episodes was observed. However, these studies also report that this observed pattern of lower recurrence was not sustained once the agent was stopped.

---

What Research Gaps and Uncertainties Remain

The current research landscape indicates several areas where more study is needed, including a limited number of contemporary randomized clinical trials designed to modern standards. Furthermore, strong in vitro activity against multi-drug resistant strains lacks full clinical validation in human patients, and data for certain groups remain insufficient, including for pediatric or complicated patient populations.

Common questions about Lotal (FAQ)

---

Q: Can taking Lotal make me feel tired or drowsy?

Regulatory documents indicate that tiredness or drowsiness are not among the commonly observed side effects of Lotal. However, very rare nervous system effects are listed, including fatigue and vertigo (dizziness). Patients should be aware that such symptoms have been reported in a small number of cases.

---

Q: Do I need to take Lotal at a specific time of day?

Official administration guidelines emphasize that Lotal is directed to be taken in divided daily doses—such as three times daily or approximately every 8 hours. The focus is on maintaining consistent levels of the active substance in the body, rather than requiring administration at a specific morning or evening time.

---

Q: Can I use Lotal if I am also taking vitamins or supplements?

Official labeling documents state that Lotal has a significant interaction risk with substances that contain divalent or trivalent cations. These cations are common components found in some vitamins, mineral supplements (like iron, zinc, or magnesium), and certain antacids. Taking Lotal alongside these products is described as potentially reducing the systemic uptake of Lotal.

---

Q: Is it common to feel slightly dizzy when first starting Lotal?

Vertigo (dizziness) is categorized as a very rare side effect in the official product information. Regulatory documents do not specifically address whether this effect is more common during the initial days of treatment. As the effect is classified as very rare, it is generally not anticipated to be common at any point during use.

---

Q: Are there specific tests I need before starting Lotal?

The official product information states that Lotal is contraindicated for patients with severe renal (kidney) or hepatic (liver) impairment. This requires a clinical assessment to determine eligibility, which may include reviewing organ function data to ensure the patient meets the necessary criteria.

---

Q: Is Lotal related to any other popular drugs?

Lotal's active ingredient, Nitroxoline, is classified chemically as a hydroxyquinoline derivative. This places it in a specific class of chemical compounds and helps distinguish it structurally and mechanistically from other groups of antiinfective agents.

---

Q: Are there specific warnings for women who are pregnant or breastfeeding regarding Lotal?

Lotal is explicitly contraindicated (must not be used) during lactation (breastfeeding). Official regulatory labeling documents are often silent or unclear regarding the full risk status for pregnancy, and this information is not consistently detailed as an absolute contraindication.

---

Q: What is the most serious, but rare, side effect of Lotal?

Official labels list rare adverse effects, including allergic changes to the blood count, and very rare effects impacting the nervous system, such as vertigo and insecurity of gait. Regulatory bodies classify adverse effects by frequency, but the official product information does not provide a ranking of these serious, rare reactions by subjective severity.

---

Q: Does Lotal cause any changes to my mood or mental state?

Official labeling notes effects on the nervous system, such as vertigo, fatigue, headaches, and insecurity of gait, as very rare side effects. Changes to mood, such as anxiety or depression, are not explicitly listed among the adverse reactions impacting the nervous system.

How to Store and Dispose of Lotal?

Lotal must be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F), with permitted temperature excursions. Protect the medicine from moisture by keeping it in the original, tightly closed container; the desiccant must not be removed. Do not expose the medicine to excessive heat or humidity, and do not freeze the product.

Keep Lotal and all other medicines secured and out of the reach of children and pets at all times.

Disposal of Lotal: Unused or expired Lotal should first be disposed of through a drug take-back program or mail-back disposal option if one is available. If these options are not readily accessible, the medicine may be mixed with an undesirable material, such as used coffee grounds or cat litter, placed in a sealed plastic bag, and then discarded in the household trash. Do not flush Lotal down a toilet or pour it down a drain.